XFOR
X4 Pharmaceuticals Inc
2.80$
-2.4%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -20.0% | +968.6% | -55.7% | +346.3% | -23.5% | -4.6% | +32.8% | -5.4% | -0.6% | +98.3% | |
| – | -31.8% | +1,291.4% | -55.9% | +268.5% | -35.6% | +5.5% | +46.4% | -5.1% | -8.1% | +133.2% | |
| – | -55.1% | +2,430.2% | -60.0% | +310.3% | -37.4% | +3.6% | +48.8% | -18.5% | -43.9% | +289.7% | |
| – | -55.1% | +2,430.2% | -60.0% | +310.3% | -37.4% | +3.6% | +48.8% | -6.2% | -10.6% | +147.9% | |
| – | -12.7% | +19.6% | +77.8% | -30.1% | -54.1% | -18.5% | +54.2% | -51.2% | +204.3% | -66.5% | |
| – | – | -71.5% | – | – | – | – | – | – | – | +59.0% | |
| – | – | +829.7% | -29.9% | +880.1% | +289.4% | +11.2% | -89.2% | – | – | – | |
| – | – | – | – | – | +0.0% | -36.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | – | -7.5% | |
| – | +75.2% | -7.3% | -36.1% | +118.5% | +59.1% | +5.4% | +54.5% | +17.9% | +29.3% | -16.2% | |
| – | +80.6% | -11.4% | -49.5% | +75.0% | +26.5% | +17.4% | +59.2% | +2.4% | +43.8% | -21.7% | |
| – | +106.3% | -54.9% | -27.1% | -46.8% | -12.5% | +137.9% | +34.4% | -56.3% | +13.8% | -20.5% | |
| – | +288.9% | +15.1% | -71.2% | +283.1% | +50.6% | +36.2% | +81.6% | +15.0% | -3.6% | -33.9% | |
| – | – | -2.0% | -20.4% | +154.6% | +65.1% | -0.1% | -2.5% | +68.9% | +38.2% | +1.1% | |
| – | – | – | -63.2% | +498.2% | -43.7% | -11.5% | +15.0% | -31.0% | -56.7% | +741.1% | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.6% | -85.6% | +23,944.0% | -16.3% | +74.1% | +28.3% | +146.7% | +179.9% | +13.1% | +531.0% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.